COBI placebo

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Acquired Immunodeficiency SyndromeHIVHIV InfectionsHIV-1 Infection

Phase 2

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT00892437

Gilead SciencesHIV-1 Infection

Start: 2009-05-31End: 2015-01-31Updated: 2016-02-15

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

CompletedNCT01565850

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2012-04-30End: 2014-02-28Updated: 2016-04-11

Phase 3

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01108510

Gilead SciencesHIV, HIV Infections

Start: 2010-04-30End: 2015-04-30Updated: 2016-05-23

Related Papers

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.

2017-11-1632 citations

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

2017-01-015 citations

No Resistance and Improved Renal and Bone Profiles with a Single-Table Regimen of D/C/F/TAF

MD Conference Express2014-11-01